PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21034736-7	2011	Montelukast treatment also decreased mRNA levels of IL-6, IL-10, IL-13, and TGF-beta1, all of which were elevated in fibrotic lungs.	montelukast	0-11	interleukin 13	Mus musculus	65-70	
28647381-8	2017	Montelukast significantly attenuated the poly I:C-induced increase in the number of eosinophils and levels of IL-13, IL-9, and CCL3 in BALF and airway hyperresponsiveness in both the reliever and controller models.	montelukast	0-11	interleukin 13	Mus musculus	110-115	
24126112-5	2013	The administration of montelukast caused a reduction in elevated interleukin (IL)-4, IL-13, eotaxin, immunoglobulin (Ig), inflammatory cell infiltration into the airways, and mucus production after repeated OVA challenges.	montelukast	22-33	interleukin 13	Mus musculus	85-90	
21034736-11	2011	These results suggest that montelukast exhibits its beneficial effects by inhibiting the overexpression of IL-6, IL-10, IL-13, and TGF-beta1 and by modulating the homeostatic balance between the cysteinyl-leukotriene type 1 and type 2 receptors.	montelukast	27-38	interleukin 13	Mus musculus	120-125	
20590630-10	2010	Goblet cell metaplasia and Th2-type cytokines, interleukin (IL)-4, IL-5 and IL-13, in BAL fluid were decreased with montelukast treatment.	montelukast	116-127	interleukin 13	Mus musculus	76-81